Biogennix’s DirectCell Advanced Bone Grafting System Used in 500th Case
Biogennix’s team of bone regeneration experts specifically designed this system to provide surgeons and hospitals with a comprehensive bone graft solution in a single product. The DirectCell System includes a bone graft product with advanced bone regeneration properties along with novel instrumentation engineered to harvest high concentrations of patient stem cells.
The cell-stimulating graft within the system is the advanced synthetic bone graft, Agilon, which is available in a Moldable and Strip form. Agilon products are based on Biogennix’s unique TrelCor technology that contains a nanocrystalline hydroxycarbanoapatite graft surface which actively participates in bone regeneration. The DirectCell System also provides surgeons two methods of collecting bone marrow derived stem cells, either through the harvesting of stem cell aspirate (SCA) with significantly higher stem cell counts [compared to standard bone marrow aspirate (BMA)], or marrow-rich autograft dowels.
Together, the technologies within the DirectCell System allow surgeons to leverage both advanced material properties and the power of a patient’s own stem cells.
“The DirectCell System provides surgeons the means to harvest tissue with high stem cell counts and combine it with a graft material that is actively involved in the cellular bone formation response,” said Mark Borden, PhD, Biogennix’s CTO. “This results in an optimal biological graft that immediately begins the bone regeneration process.”
The DirectCell System is growing in multiple market segments, currently seeing strongest growth with spine surgeons and foot and ankle surgeons.
Dr. Jeffrey Wang, Chief of Orthopaedic Spine Service at USC and Co-Director of the USC Spine Center, has been using the DirectCell System in his spine fusion cases. “When you combine live cells with an advanced surface, you are optimizing the healing response,” said Dr. Wang. “Surgeons and hospitals alike need innovative solutions with strong scientific backing, which incorporate new biological technologies.”
Dr. Brett Sachs, reconstructive foot and ankle surgeon and Program Director for the Highlands-Presbyterian/St. Luke's Residency Program, is using the DirectCell System for major reconstructive cases. “I like that I can harvest marrow rich autograft dowels from the calcaneus or tibia, and blend it with an advanced graft that handles and mixes extremely well,” said Dr. Sachs. “Especially for challenging cases, I feel like I’m giving my patients the best possible chance for a successful fusion.”
The DirectCell System is Biogennix’s latest innovation in its decade-plus history of delivering advanced bone graft technologies to the market.
“As a company our strength has always been our focus and deep expertise in advanced bone regeneration technologies,” said Biogennix CEO Chris MacDuff. “I attribute the swift success of the DirectCell System primarily to the solid science supporting its benefits.”
MacDuff also described the need for solutions that are not only clinically effective, but safe for patients.
“When you use the patient’s own cells, you completely eliminate the risk of disease transmission that has recently been seen with a cadaver-based stem cell products,” said MacDuff. “The DirectCell System not only enables the harvest of significantly higher cell counts, but it is a safer and significantly more cost-effective alternative.”
Biogennix® is a market leader in advanced bone regeneration technologies. Biogennix is headquartered in Irvine, CA where they develop, manufacture, and distribute proprietary technologies used in bone fusion procedures. Biogennix team members are experts in bone graft science who are focused on creating solutions that keep distributors and surgeons on the forefront of bone regeneration. Learn more at biogennix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517006045/en/
Paul Williams, 310-569-0023, email@example.com
View this news release online at: